TEAM

CURRENT MEMBERS

Postdoctoral researchers

Picture1.jpg

The role of connexins, pannexins and their channels in cholestasis

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Alanah Pieters

20191012_183818.jpg

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Bruna dos Santos Rodrigues

Profile_Picture_Andrés_Tabernilla.jpg

Development and testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. M. Sci. Andrés Tabernilla

Foto.jpg

Testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. D.V.M. Prashant Kadam

Doctoral researchers

Pharm. Axelle Cooreman.jpg

Pharm. Axelle Cooreman

The role of connexins, pannexins and their channels in cholestasis

To be defended in 2022

Promoters: Mathieu Vinken, Pieter Annaert

Pharm. Eva Gijbels.jpg

Pharm. Eva Gijbels

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be defended in 2022

Promoters: Mathieu Vinken, Lindsey Devisscher

Co-promoter: Tamara Vanhaecke

Emma Gustafson.jpg

M. Sci Emma Gustafson

Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study

To be defended in 2022

Promoters: Mathieu Vinken, Tamara Vanhaecke

M. Sci Kaat Leroy.jpg

M. Sci Kaat Leroy

The role of connexins, pannexins and their channels in liver cancer

To be defended in 2022

Promoter: Mathieu Vinken

Co-promoter: Bruno Cogliati

Pharm. Raf Van Campenhout.jpg

Pharm. Raf Van Campenhout

Development of new inhibitors of connexin hemichannels and pannexin channels as novel therapeutics for the treatment of liver disease

To be defended in 2022

Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans

caufriez_Anne.jpg

M. Pharm. Sci. Anne Caufriez

Development and in vitro testing of new inhibitors of pannexin1 channels

To be defended in 2023

Promoters: Mathieu Vinken, Steven Ballet

 

 

 

 

 

 

 

 

 

 

 

 

Scientific collaborators

IMG_6160 (2).jpg

The role of connexin43 hemichannels and pannexin1 channels in liver cancer

To be defended in 2024 (University of São Paulo-Brazil)

Promoters: Bruno Cogliati, Mathieu Vinken

M. Sci. Cícero Júlio Silva Costa

Picture1.jpg

Development of new inhibitors of connexin43 hemichannels

To be completed in 2021

Promoter: Mathieu Vinken

M. Sci. Ana Rita Coelho Gomes

 

 

Technicians

Foto Manon Wery.JPG

   Manon Wery

 

 

Project manager

 

 

 

 

 

 

 

 

 

 

 

       

 

 

 

 

 

FORMER TEAM MEMBERS

profile photo JZ.jpg

Julia Zajac

Dr. Vânia Vilas-Boas

M. Sci. Sara Crespo-Yanguas

Pharm. Michaël Maes

Pharm. Joost Willebrords

Miss Dinja De Win

Miss Tâmara Prandini

Miss Tineke Vanhalewyn

FINISHED POSTDOCTORAL PROJECTS

Role of connexin and pannexin (hemi)channels in liver cancer

Tereza Cristina da Silva: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

Role of connexin and pannexin (hemi)channels in hepatitis

Isabel Veloso Alves Pereira: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury

Vânia Vilas-Boas: completed 31/12/2020

Promoter: Mathieu Vinken

 

 

FINISHED DOCTORAL PROJECTS

Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures

Tatyana Doktorova: defended 16/03/2012

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes

Eva Ramboer: defended 15/10/2015

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

The role of connexins, pannexins and their channels in acute liver failure

Michaël Maes: defended 17/10/2017

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis

Joost Willebrords: defended 29/01/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in liver fibrosis

Sara Crespo Yanguas: defended 25/10/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

Connexin43 hemichannels as druggable targets for future anti-seizure medication

Laura Walrave: defended 24/01/2019

Promoter: Ilse Smolders

Co-promoters: Mathieu Vinken, Luc Leybaert

© 2023 by InVitroTox Consulting.

Proudly created using Wix.com

  • LinkedIn Social Icon